GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma

Autor: Gallego, S., Bernabeu, D., Garrido-Pontnou, M., Guillen, G., Hindi, N., Juan-Ribelles, A., Marquez, C., Mata, C., Orcajo, J., Ramirez, G., Ramos, M., Romagosa, C., Ruano, D., Rubio, P., Verges, R., Valverde, C., GEIS Grp Espanol Invest Sarcomas, SEHOP Soc Espanola Hematologia Onc
Rok vydání: 2021
Předmět:
Zdroj: CLINICAL & TRANSLATIONAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
ISSN: 1699-048X
Popis: Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma (STS) in children and adolescents. In Spain the annual incidence is 4.4 cases per million children < 14 years. It is an uncommon neoplasm in adults, but 40% of RMS are diagnosed in patients over 20 years of age, representing 1% of all STS in this age group. RMS can appear anywhere in the body, with some sites more frequently affected including head and neck, genitourinary system and limbs. Assessment of a patient with suspicion of RMS includes imaging studies (MRI, CT, PET-CT) and biopsy. All patients with RMS should receive chemotherapy, either at diagnosis in advanced or metastatic stages, or after initial resection in early local stages. Local control includes surgery and/or radiotherapy depending on site, stage, histology and response to chemotherapy. This guide provides recommendations for diagnosis, staging and treatment of this neoplasm.
Databáze: OpenAIRE
Externí odkaz: